AUTHOR=Bridel Claire , Eijlers Anand J. C. , van Wieringen Wessel N. , Koel-Simmelink Marleen , Leurs Cyra E. , Schoonheim Menno M. , Killestein Joep , Teunissen Charlotte E. 

TITLE=No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

JOURNAL=Frontiers in Molecular Neuroscience

VOLUME=11

YEAR=2018

URL=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2018.00371

DOI=10.3389/fnmol.2018.00371

ISSN=1662-5099

ABSTRACT=<p><bold>Background:</bold> The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking.</p><p><bold>Objective:</bold> We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients.</p><p><bold>Methods:</bold> The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins.</p><p><bold>Results:</bold> In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years.</p><p><bold>Conclusions:</bold> Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.</p>